https://www.selleckchem.com/pr....oducts/pqr309-bimira
benefit most from further etiological clarification. Further potential utility in clinical routine and clinical trials is discussed. PD-L1 PET imaging allows for the whole body measuring its expression across primary and metastatic tumors and visualizing its spatiotemporal dynamics before, during, and after treatment. In this study, we reported a novel F-labeled D-peptide antagonist, F-NOTA-NF12, for PET imaging of PD-L1 status in preclinical and first-in-human studies. Manual and automatic radiosynthesis of F-NOTA-NF12 was p
Like
Comment
Share
